{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,6]],"date-time":"2026-03-06T09:27:43Z","timestamp":1772789263878,"version":"3.50.1"},"reference-count":29,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,3,6]],"date-time":"2026-03-06T00:00:00Z","timestamp":1772755200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:p>An unexpected, isolated prolongation of activated partial thromboplastin time (APTT) frequently poses diagnostic challenges in coagulation laboratories. This article presents two patients exhibiting isolated prolonged APTT, one with significant bleeding manifestations and another without bleeding symptoms. The first patient was diagnosed with acquired hemophilia A (AHA), whereas antiphospholipid antibodies (aPLs) were suspected to be responsible for the isolated prolonged APTT in the second patient. Accurate identification of the underlying cause of isolated prolonged APTT is crucial for proper diagnosis and subsequent therapeutic management. Furthermore, we summarize potential causes of isolated prolonged APTT and propose a simplified diagnostic algorithm to distinguish between lupus anticoagulants (LA) (more common) and coagulation factor deficiencies (less common). This report aims to provide insights into the clinical management of similar cases in the future.<\/jats:p>","DOI":"10.3389\/fimmu.2026.1735963","type":"journal-article","created":{"date-parts":[[2026,3,6]],"date-time":"2026-03-06T06:42:20Z","timestamp":1772779340000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Case Report: Differential diagnosis and clinical management of isolated prolonged activated partial thromboplastin time"],"prefix":"10.3389","volume":"17","author":[{"given":"Lu","family":"Liu","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dongmei","family":"Guo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2026,3,6]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1111\/ejh.13394","article-title":"Unexpected, isolated activated partial thromboplastin time prolongation: A practical mini-review","volume":"104","author":"Rasmussen","year":"2020","journal-title":"Eur J haematology"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1007\/s00296-017-3878-z","article-title":"Length of exposure to antiphospholipid antibodies, rather than age, is a risk factor for thrombosis: a retrospective single-centre observational study","volume":"38","author":"Les","year":"2018","journal-title":"Rheumatol Int"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/keaa857","article-title":"Antiphospholipid patterns predict risk of thrombosis in systemic lupus erythematosus","volume":"60","author":"Demir","year":"2021","journal-title":"Rheumatol (Oxford England)"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1111\/jth.15047","article-title":"Guidance from the Scientific and Standardization Committee for lupus anticoagulant\/antiphospholipid antibodies of the International Society on Thrombosis and Haemostasis: Update of the guidelines for lupus anticoagulant detection and interpretation","volume":"18","author":"Devreese","year":"2020","journal-title":"J Thromb haemostasis: JTH"},{"key":"B5","doi-asserted-by":"publisher","first-page":"695","DOI":"10.1002\/rth2.12245","article-title":"Ruling out lupus anticoagulants with mixing test-specific cutoff assessment and the index of circulating anticoagulant","volume":"3","author":"Kumano","year":"2019","journal-title":"Res Pract Thromb haemostasis"},{"key":"B6","doi-asserted-by":"publisher","first-page":"e26608","DOI":"10.1097\/md.0000000000026608","article-title":"Differential diagnosis and clinical management of isolated prolonged activated partial thromboplastin time in a patient with Hashimoto thyroiditis-associated thyroid cancer: A case report","volume":"100","author":"Zhong","year":"2021","journal-title":"Medicine"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.25669","article-title":"Coagulation mixing studies: Utility, algorithmic strategies and limitations for lupus anticoagulant testing or follow up of abnormal coagulation tests","volume":"95","author":"Favaloro","year":"2020","journal-title":"Am J Hematol"},{"key":"B8","article-title":"Detection and quantitative evaluation of lupus circulating anticoagulant activity","volume":"57","author":"Rosner","year":"1987","journal-title":"Thromb haemostasis"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1515\/cclm-2018-0794","article-title":"Determining the cutoff value of the APTT mixing test for factor VIII inhibitor","volume":"57","author":"Tang","year":"2019","journal-title":"Clin Chem Lab Med"},{"key":"B10","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1186\/s43162-021-00074-9","article-title":"Acquired hemophilia A (AHA): underreported, underdiagnosed, undertreated medical condition","volume":"34","author":"El Demerdash","year":"2022","journal-title":"Egyptian J Internal Med"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1097\/MBC.0b013e32832ca388","article-title":"The prognosis and treatment of acquired hemophilia: a systematic review and meta-analysis","volume":"20","author":"Bitting","year":"2009","journal-title":"Blood coagulation fibrinolysis: an Int J haemostasis Thromb"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2019.230771","article-title":"International recommendations on the diagnosis and treatment of acquired hemophilia A","volume":"105","author":"Tiede","year":"2020","journal-title":"Haematologica"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1111\/j.1471-0528.2012.03469.x","article-title":"Pregnancy-associated acquired haemophilia A: results from the European Acquired Haemophilia (EACH2) registry","volume":"119","author":"Tengborn","year":"2012","journal-title":"BJOG: an Int J obstetrics gynaecology"},{"key":"B14","doi-asserted-by":"publisher","first-page":"1597","DOI":"10.3390\/jcm14051597","article-title":"Acquired hemophilia-A case series and review","volume":"14","author":"Waldman Radinsky","year":"2025","journal-title":"J Clin Med"},{"key":"B15","doi-asserted-by":"publisher","first-page":"420","DOI":"10.3390\/diagnostics13030420","article-title":"Acquired hemophilia A: an update on the etiopathogenesis, diagnosis, and treatment","volume":"13","author":"Zanon","year":"2023","journal-title":"Diagnostics (Basel Switzerland)"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2008.001743","article-title":"International recommendations on the diagnosis and treatment of patients with acquired hemophilia A","volume":"94","author":"Huth-K\u00fchne","year":"2009","journal-title":"Haematologica"},{"key":"B17","doi-asserted-by":"publisher","first-page":"295","DOI":"10.1111\/j.1538-7836.2006.01753.x","article-title":"International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS)","volume":"4","author":"Miyakis","year":"2006","journal-title":"J Thromb haemostasis: JTH"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1016\/j.thromres.2012.08.270","article-title":"Antiphospholipid antibodies: evaluation of the thrombotic risk","author":"Devreese","year":"2012","journal-title":"Thromb Res"},{"key":"B19","doi-asserted-by":"publisher","first-page":"1169","DOI":"10.3390\/medicina59061169","article-title":"Isolated prolongation of activated partial thromboplastin time: not just bleeding risk","volume":"59","author":"Santoro","year":"2023","journal-title":"Med (Kaunas Lithuania)"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1080\/10408363.2019.1650714","article-title":"Post-translational modifications of proteins in antiphospholipid antibody syndrome","volume":"56","author":"Buttari","year":"2019","journal-title":"Crit Rev Clin Lab Sci"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMra1705454","article-title":"Diagnosis and management of the antiphospholipid syndrome","volume":"378","author":"Garcia","year":"2018","journal-title":"New Engl J Med"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1016\/j.autrev.2009.11.013","article-title":"The geoepidemiology of the antiphospholipid antibody syndrome","volume":"9","author":"Biggioggero","year":"2010","journal-title":"Autoimmun Rev"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1177\/0961203314545410","article-title":"Persistent antiphospholipid antibody (aPL) in asymptomatic carriers as a risk factor for future thrombotic events: a nationwide prospective study","volume":"23","author":"Mustonen","year":"2014","journal-title":"Lupus"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1016\/j.autrev.2013.08.001","article-title":"Autoantibodies to coagulation factors: from pathophysiology to diagnosis and therapy","volume":"13","author":"Cugno","year":"2014","journal-title":"Autoimmun Rev"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1309\/c8t8-ynb4-g3w4-5prf","article-title":"Comparison of three methods for measuring factor VIII levels in plasma","volume":"120","author":"Chandler","year":"2003","journal-title":"Am J Clin Pathol"},{"key":"B26","article-title":"A chromogenic assay allows reliable measurement of factor VIII levels in the presence of strong lupus anticoagulants","volume":"79","author":"de Maistre","year":"1998","journal-title":"Thromb haemostasis"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.23723","article-title":"Chromogenic factor VIII activity assay","volume":"89","author":"Moser","year":"2014","journal-title":"Am J Hematol"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1007\/s00277-022-04972-y","article-title":"Usefulness of anti-factor VIII IgG ELISA in acquired hemophilia A follow-up","volume":"101","author":"Chansavang","year":"2022","journal-title":"Ann Hematol"},{"key":"B29","article-title":"An ELISA system to detect anti-factor VIII antibodies without interference by lupus anticoagulants. Preliminary data in hemophilia A patients","volume":"85","author":"Blanco","year":"2000","journal-title":"Haematologica"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2026.1735963\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,6]],"date-time":"2026-03-06T06:42:36Z","timestamp":1772779356000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2026.1735963\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,6]]},"references-count":29,"alternative-id":["10.3389\/fimmu.2026.1735963"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2026.1735963","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,6]]},"article-number":"1735963"}}